Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026)
Neurocrine Biosciences' (NBIX) quarterly Amortization - Intangibles came in at $16.4 million in Q2 2026, up 1540.0% on a YoY basis from $1.0 million in Q2 2025, and up 1540.0% quarter-over-quarter from $1.0 million in Q2 2025.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Amortization - Intangibles (2025 - 2026) Analysis & Trends
Neurocrine Biosciences (NBIX) has reported Amortization - Intangibles for 2 consecutive years, with $16.4 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.53 Bn | 625.77 Bn | 17.26 Bn |
| 2 | AbbVie | 442.27 Bn | 435.70 Bn | 12.70 Bn |
| 3 | Merck | 366.81 Bn | 359.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn |
| 5 | Pfizer | 159.37 Bn | 147.67 Bn | 10.94 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.12 Bn | 44.12 Bn | - |
| 8 | Incyte | 25.49 Bn | 20.95 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.55 Bn | 18.89 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |